EUVIMEDEUVIMED entdecken
Fall-Kontroll-StudieOpen Access · CC BY 4.0

Blood Biomarkers of Neurodegeneration over Four Decades After Toxic Oil Syndrome: A Case-Control Study

Mariano Ruiz-Ortiz iD, José Lapeña-Motilva iD, Verónica Giménez de Bejar, Fernando Bartolomé iD, Carolina Alquézar iD, Minerva Martínez-Castillo iD, Sonia Wagner-Reguero, Teodoro Del Ser iD, María Antonia Nogales, Sonia Álvarez-Sesmero iD, Montserrat Morales, Cecilia García-Cena iD und 1 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26115122 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Mariano Ruiz-Ortiz und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, 12 de Octubre University Hospital, 28041 Madrid, Spain. Hauptthemen laut MEDLINE: Biomarkers, Neurodegenerative Diseases, Neurotoxicity Syndromes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, European Union's 'NextGenerationEU'/PRTR, European Union’s ‘NextGenerationEU’/PRTR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Toxic oil syndrome (TOS) is a multisystemic disease that emerged in Spain in 1981 due to the ingestion of aniline-adulterated rapeseed oil fraudulently sold as olive oil. Although neurological sequelae, including cognitive deficits, have been documented in long-term survivors, it remains unclear whether TOS leads to chronic or progressive neurodegeneration. In this case-control study, we measured blood concentrations of neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and phosphorylated tau 217 (pTau217) in 50 individuals with clinically confirmed TOS and 50 matched healthy controls. Biomarkers were quantified using ultrasensitive immunoassay platforms (Quanterix SIMOA SR-X and Fujirebio Lumipulse G600II). Group differences were evaluated using non-parametric tests, and multiple linear regression was applied to assess associations between biomarkers and clinical variables. While NfL levels were slightly higher in TOS patients (p = 0.025), no significant group differences were observed for pTau217 or GFAP. Age was a consistent predictor of biomarker levels, particularly for GFAP and pTau217, and female sex was independently associated with higher GFAP concentrations. Lower educational attainment was linked to increased NfL levels. Clinical status (TOS vs. control) did not significantly predict biomarker concentrations in any model. These findings suggest no evidence of overt or ongoing neurodegeneration in long-term TOS survivors as detected by current blood biomarkers. However, the possibility of subtle, compartmentalized, or slowly evolving neurotoxic processes cannot be excluded. Future longitudinal studies incorporating serial biomarker assessments, advanced neuroimaging, and oxidative stress markers are warranted to clarify the long-term neurological consequences of TOS and to detect subclinical trajectories of delayed neurotoxicity in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersNeurodegenerative DiseasesNeurotoxicity SyndromesHumansFemaleMaleCase-Control StudiesMiddle AgedGlial Fibrillary Acidic ProteinNeurofilament ProteinsAgedtau ProteinsAdult

Stichwörter der Autor:innen

biomarkersenvironmental toxinsglial fibrillary acidic protein (GFAP)neurodegenerationneurofilament light chain (NfL)pTau217toxic oil syndrome

Substanzen

BiomarkersGlial Fibrillary Acidic ProteinNeurofilament Proteinstau Proteinsneurofilament protein LGFAP protein, human

Autor:innen und Institutionen

  • Department of Neurology, 12 de Octubre University Hospital, 28041 Madrid, Spain.
  • Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain.
  • Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), 28029 Madrid, Spain.
  • Alzheimer's Centre Reina Sofía-CIEN Foundation, Instituto de Salud Carlos III, 28031 Madrid, Spain.
  • Department of Internal Medicine, 12 de Octubre University Hospital, 28041 Madrid, Spain.
  • Department of Psychiatry, 12 de Octubre University Hospital, 28041 Madrid, Spain.

ORCID-Profile: Mariano Ruiz-Ortiz, José Lapeña-Motilva, Fernando Bartolomé, Carolina Alquézar, Minerva Martínez-Castillo, Teodoro Del Ser, Sonia Álvarez-Sesmero, Cecilia García-Cena, Julián Benito-León

Förderung

  • NINDS NIH HHS
  • European Union's 'NextGenerationEU'/PRTR
  • European Union’s ‘NextGenerationEU’/PRTR

Zitieren

APA

Ruiz-Ortiz, M., Lapeña-Motilva, J., Giménez de Bejar, V., Bartolomé, F., Alquézar, C., Martínez-Castillo, M., Wagner-Reguero, S., Del Ser, T., Nogales, M. A., Álvarez-Sesmero, S., Morales, M., García-Cena, C., & Benito-León, J. (2025). Blood Biomarkers of Neurodegeneration over Four Decades After Toxic Oil Syndrome: A Case-Control Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26115122

Vancouver

Ruiz-Ortiz M, Lapeña-Motilva J, Giménez de Bejar V, Bartolomé F, Alquézar C, Martínez-Castillo M, et al. Blood Biomarkers of Neurodegeneration over Four Decades After Toxic Oil Syndrome: A Case-Control Study. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26115122

BibTeX
@article{RuizOrtiz2025,
  author = {Ruiz-Ortiz, Mariano and Lapeña-Motilva, José and Giménez de Bejar, Verónica and Bartolomé, Fernando and Alquézar, Carolina and Martínez-Castillo, Minerva and Wagner-Reguero, Sonia and Del Ser, Teodoro and Nogales, María Antonia and Álvarez-Sesmero, Sonia and Morales, Montserrat and García-Cena, Cecilia and Benito-León, Julián},
  title = {Blood Biomarkers of Neurodegeneration over Four Decades After Toxic Oil Syndrome: A Case-Control Study},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26115122}
}
Kostenlos starten →